<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>9(2)</volume><submitter>van der Meer PB</submitter><pubmed_abstract>&lt;h4>Background&lt;/h4>This study aimed at investigating antiepileptic drug (AED) prescription preferences in patients with brain tumor-related epilepsy (BTRE) among the European neuro-oncology community, the considerations that play a role when initiating AED treatment, the organization of care, and practices with regard to AED withdrawal.&lt;h4>Methods&lt;/h4>A digital survey containing 31 questions about prescription preferences of AEDs was set out among members of the European Association of Neuro-Oncology (EANO).&lt;h4>Results&lt;/h4>A total of 198 respondents treating patients with BTRE participated of whom 179 completed the entire survey. Levetiracetam was the first choice in patients with BTRE for almost all respondents (90% [162/181]). Levetiracetam was considered the most effective AED in reduci</pubmed_abstract><journal>Neuro-oncology practice</journal><pagination>105-113</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC8965049</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Prescription preferences of antiepileptic drugs in brain tumor patients: An international survey among EANO members.</pubmed_title><pmcid>PMC8965049</pmcid><pubmed_authors>Preusser M</pubmed_authors><pubmed_authors>Koekkoek JAF</pubmed_authors><pubmed_authors>van den Bent MJ</pubmed_authors><pubmed_authors>van der Meer PB</pubmed_authors><pubmed_authors>Dirven L</pubmed_authors><pubmed_authors>Taphoorn MJB</pubmed_authors><pubmed_authors>Ruda R</pubmed_authors></additional><is_claimable>false</is_claimable><name>Prescription preferences of antiepileptic drugs in brain tumor patients: An international survey among EANO members.</name><description>&lt;h4>Background&lt;/h4>This study aimed at investigating antiepileptic drug (AED) prescription preferences in patients with brain tumor-related epilepsy (BTRE) among the European neuro-oncology community, the considerations that play a role when initiating AED treatment, the organization of care, and practices with regard to AED withdrawal.&lt;h4>Methods&lt;/h4>A digital survey containing 31 questions about prescription preferences of AEDs was set out among members of the European Association of Neuro-Oncology (EANO).&lt;h4>Results&lt;/h4>A total of 198 respondents treating patients with BTRE participated of whom 179 completed the entire survey. Levetiracetam was the first choice in patients with BTRE for almost all respondents (90% [162/181]). Levetiracetam was considered the most effective AED in reduci</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Apr</publication><modification>2025-04-04T07:33:33.959Z</modification><creation>2024-11-15T22:40:08.237Z</creation></dates><accession>S-EPMC8965049</accession><cross_references><pubmed>35371521</pubmed><doi>10.1093/nop/npab059</doi></cross_references></HashMap>